Clinical Trial Update: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial assesses JSB462 (Luxdegalutamide) in combination with Lutetium-177 vipivotide tetraxetan for metastatic castration-resistant prostat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lutetium-177 Vipivotide Tetraxetan (lutetium-177 vipivotide tetraxetan)
• Luxdegalutamide (Luxdegalutamide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostatic Cancer, Castration-Resistant | Phase 2 | Status: ACTIVE_NOT_RECRUITING